The new Qiagen reagent "xHYB" launched in 2022. Would you like to detect viruses and bacteria in environmental samples such as wastewater and river water using NGS?
Collaboration plan between Qiagen and our company, Danaform. Contract services for four types of panels targeting bacteria, viruses, and antibiotic resistance genes. Each panel is priced at 80,000 yen per sample, with quantity discounts available starting from 50,000 yen.
Inquire About This Product
basic information
Four types of panels: 1. xHYB AMR Panel - Detects over 2,700 antibiotic resistance genes in bacteria. 2. xHYB Respiratory Panel - Detects 89 types of respiratory infection viruses, including COVID-19 and influenza. 3. xHYB Viral STI Panel - Detects viruses such as HBV, HIV-1, and HPV. 4. xHYB Adventitious Agent Panel - Detects viruses that could contaminate bioreactors used in pharmaceutical manufacturing. The delivery data includes two sets: (1) analysis data from the Qiagen portal site GeneGlobe (a list of target detections), and (2) graphs created by Danaform (featuring highly visible bar graphs and donut charts). Analysis data will be delivered via USB.
Price range
P2
Delivery Time
※Delivery time is approximately 5-7 weeks.
Applications/Examples of results
For the detection of bacteria and viruses in environmental samples such as river water and wastewater. User feedback and usage examples: - I usually detect a specific type of bacteria using quantitative PCR. With the introduction of this panel, I would like to use it to regularly check if there are any unexpected bacteria present that I hadn't anticipated. - I want to investigate the wastewater coming from factories and hospitals. I plan to collect river water and check for the presence of viruses with antibiotic resistance genes, aiming to improve water quality.
Detailed information
-
Delivery Data 1: Data from the list provided by Qiagen GeneGlobe Delivery Data 2: Data from the original graph of Danaform
catalog（1）
Download All Catalogs
Company information
Danaform Inc. is a company established in 1998, based on the RIKEN Venture System of the National Research and Development Agency RIKEN, with Yoshihide Hayasaki from RIKEN (who has been the representative director of Danaform Inc. since 2021) at its core. The company is actively engaged in gene analysis and genetic testing, focusing on technologies co-developed by Danaform and RIKEN, including contract analysis using next-generation sequencers such as CAGE-seq and RNA-seq, the sale of fluorescent reagents Eprobe capable of SNP detection, and the sale of various clones, boasting a significant inventory. Moving forward, we aim to refine our proprietary technologies and strive for higher quality research and manufacturing as experts in the field of genetics, with the hope of contributing to people's health.
